KHCF Signs MOU With Jordan Phosphate Mines Company
Amman, April 21, 2024 - The King Hussein Cancer Foundation (KHCF) signed a Memorandum of Understanding (MOU) with the Jordan Phosphate Mines Company. Under this agreement, the Company will equip the medical laboratories section of the King Hussein Cancer Center’s (KHCC) King Abdullah II bin Al Hussein Building in Aqaba with the latest medical devices and equipment. As an appreciation for this donation, the laboratory will be named after the Company.
The MOU was signed by Mrs. Nisreen Qatamish, Director General of KHCF, and Eng. Abdel Wahab Al Rowwad, CEO of Jordan Phosphate Mines Company.
During the signing ceremony, HRH Princess Ghida Talal, Chairperson of KHCF and KHCC, emphasized that support from organizations such as Jordan Phosphate Mines Company is integral to maintaining KHCC’s high level and standard of treatment and care for its patients.
H.E Dr. Mohammed Thneibat, Chairman of the Board of Directors of Jordan Phosphate Mines Company, expressed the pride in the Company’s partnership with KHCF to support its efforts to provide a suitable healthcare environment for cancer patients in various regions of the Kingdom. He emphasized the importance of national efforts in Jordan to provide treatment opportunities for patients – particularly those who are underprivileged.
Dr. Thneibat also stated that this support stems from the Company's sense of national responsibility and its belief in KHCF and KHCC’s leading humanitarian role in providing comprehensive care for all patients. He affirmed the Company's readiness to provide continuous support to assist the Foundation in implementing its plans to expand the provision of healthcare and therapeutic services for cancer patients in various regions of the Kingdom.
The King Abdullah II bin Al Hussein Building in Aqaba will support the healthcare sector in the southern region of Jordan by providing advanced medical care and alleviating the burden of travel to Amman, which is quite long and arduous. It will also offer diagnostic services including early detection, laboratories, and radiology services for both cancer and non-cancer patients.